Beschreibung
Meloxicam (4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1,2-benzothiazine-3carboxamide-1,1 -dioxide) is an NSAID used in the management of rheumatic disease, which is distinguished by the fact that it is well tolerated by the stomach at the doses necessary for therapy. The anti-inflammatory and pain-relieving properties of Meloxicam make this active substance very interesting for use in pain therapy. Meloxicam act as nonselective inhibitor of the enzyme cyclooxygenase (COX), inhibiting both the cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) isoenzymes. A rapid, specific isocratic RP-HPLC method has been developed for the determination of Meloxicam capsules using a UV/diode array detector. The method was validated as per ICH guidelines and USP/NF. Therefore, this method can be useful for routine analysis of Meloxicam capsules as bulk drug and dosage form.
Autorenporträt
The author has been working in the field of Pharmaceutical Chemistry since 2009. He has worked in pharmaceutical industry in the field of Analytical Research and Development and had been actively engaged in the quality control of drugs using modern analytical techniques like LCMS/MS, UHPLC, HPLC, HPTLC, NMR and Mass Spectrometry.
Herstellerkennzeichnung:
OmniScriptum SRL
Str. Armeneasca 28/1, office 1
2012 Chisinau
MD
E-Mail: info@omniscriptum.com
